INVERSAGO PHARMA
A specialized, preclinical-stage biotech company, Inversago Pharma develops new generations of peripherally-restricted cannabinoid-1 receptor (CB1) inverse agonists/ antagonists for the treatment of Prader-Willi Syndrome (PWS), Type-1 Diabetes (T1D), obesity and other metabolic disorders such as non-alcoholic steatohepatitis (NASH). Inversago’s technology addresses limits associated with first generation CB1 blockers, allowing the company to exploit their full medical potential.
INVERSAGO PHARMA
Social Links:
Industry:
Biopharma Biotechnology Health Care Medical Pharmaceutical
Founded:
2015-01-01
Address:
Montréal, Quebec, Canada
Country:
Canada
Website Url:
http://www.inversago.com
Total Employee:
1+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
42 M USD
Similar Organizations
Arbutus Biopharma
Arbutus Biopharma Corporation is a publicly-traded biopharmaceutical company.
Calimmune
Calimmune is a clinical-stage gene therapy company.
Continuous Precision Medicine
Continuous Precision Medicine™ is a leader in the fight against the opioid epidemic.
Giiant Pharma
Giiant Pharma is a preclinical-stage biotech company.
Hangzhou Just Biotherapeutics (Just China)
Hangzhou Just Biotherapeutics is a comprehensive high-tech design company.
Metera Pharmaceuticals
Metera Pharmaceuticals is a preclinical stage biotechnology company.
Neuraly
Neuraly is a startup biotech company.
Portal Instruments
Portal Instruments is an early stage company that offers medical device.
Scarless Laboratories
Scarless Laboratories is a Beverly Hills-based research-focused early-stage biotechnology company.
ZSX Medical
ZSX Medical, LLC, is a pre-clinical stage medical device company.
Current Advisors List
Current Employees Featured
Founder
Investors List
AQC Capital
AQC Capital investment in Series B - Inversago Pharma
Fonds de solidarité FTQ
Fonds de solidarité FTQ investment in Series B - Inversago Pharma
Amorchem
Amorchem investment in Series B - Inversago Pharma
JDRF T1D Fund
JDRF T1D Fund investment in Series B - Inversago Pharma
adMare Bio Innovations
adMare Bio Innovations investment in Series B - Inversago Pharma
Genesys Capital
Genesys Capital investment in Series B - Inversago Pharma
Forbion Capital Partners
Forbion Capital Partners investment in Series B - Inversago Pharma
AQC Capital
AQC Capital investment in Series A - Inversago Pharma
JDRF T1D Fund
JDRF T1D Fund investment in Series A - Inversago Pharma
Anges Quebec
Anges Quebec investment in Series A - Inversago Pharma
Key Employee Changes
| Date | New article |
|---|---|
| 2022-05-17 | Inversago Pharma Appoints Glenn S. Vraniak as Chief Financial Officer |
Official Site Inspections
http://www.inversago.com
- Host name: 141.193.213.10
- IP address: 141.193.213.10
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
